Sentinel lymph node biopsy status improves adjuvant therapy decision-making in patients with clinical stage IIB/C melanoma: A population-based analysis - 16/03/23
, Richard J. Straker, MD a, Phyllis A. Gimotty, PhD b, Emily Y. Chu, MD, PhD c, Tara C. Mitchell, MD d, John T. Miura, MD a, Michael A. Marchetti, MD e, Edmund K. Bartlett, MD f, Giorgos C. Karakousis, MD aAbstract |
Background |
Given the results of the recent KEYNOTE-716 trial, the performance of sentinel lymph node (SLN) biopsy for patients with clinical stage IIB/C melanoma has been questioned.
Objective |
Determine the utility of SLN status in guiding the recommendations for adjuvant therapy.
Methods |
Patients with clinical stage IIB/C cutaneous melanoma who underwent wide local excision and SLN biopsy between 2004 and 2011 were identified from the Surveillance, Epidemiology, and End Results database. Two prognostic models, with and without SLN status, were developed predicting risk of melanoma-specific death (MSD). The primary outcome was net benefit at treatment thresholds of 20% to 40% risk of 5-year MSD.
Results |
For the 4391 patients included, the 5-year MSD rate was 46%. The model estimating 5-year MSD risk that included SLN status provided greater net benefit at treatment thresholds from 30% to 78% compared to the model without SLN status. The added net benefit for the SLN biopsy-containing model persisted in subgroup analysis of patients in different age groups and with various T stages.
Limitations |
Retrospective study.
Conclusions |
A prognostic model with SLN status estimating patient risk for 5-year MSD provides superior net benefit compared to a model with primary tumor staging factors alone for threshold mortality rates ≥30%.
Le texte complet de cet article est disponible en PDF.Key words : decision analysis, immune therapy, melanoma, prognosis, sentinel lymph node biopsy, surgery, survival, wide local excision
Abbreviations used : AAPI, AJCC, AUC, CP, IQR, MSD, NOS, PD1, ROC, SEER, SLN, SLNB
Plan
| Drs Sharon and Straker contributed equally to this study as lead authors. |
|
| Funding sources: Dr Karakousis's efforts were supported by the National Cancer Institute SPORE in Skin Cancer, SP50 CA 261608. |
|
| IRB approval status: Reviewed by the University of Pennsylvania Institution Review Board, approval given for use of SEER data (protocol # 53183). |
|
| Patient consent: No identifiable material, including photographs or identifiable medical information, is included in this manuscript. All included data is de-identified, and as such, no IRB approval was required for this specific study, although it was required for use of the SEER data (see below). |
|
| Reprints not available from the authors. |
Vol 88 - N° 4
P. 802-807 - avril 2023 Retour au numéro
Article précédent
- Acute graft-versus-host disease presenting as Stevens–Johnson syndrome and toxic epidermal necrolysis: A retrospective cohort study
- Yi-Teng Hung, Yen-Wen Chen, Yenlin Huang, Yu-Jr Lin, Chun-Bing Chen, Wen-Hung Chung
- Impact of systemic therapies in metastatic melanoma of unknown primary: A study from MELBASE, a French multicentric prospective cohort
- Perrine Rousset, Stéphane Dalle, Laurent Mortier, Olivier Dereure, Sophie Dalac, Caroline Dutriaux, Marie-Thérèse Leccia, Delphine Legoupil, Florence Brunet-Possenti, Julie De Quatrebarbes, Jean-Jacques Grob, Philippe Saiag, Eve Maubec, Pierre-Emmanuel Stoebner, Florence Granel-Brocard, Jean-Philippe Arnault, Clara Allayous, Bastien Oriano, Céleste Lebbe, Henri Montaudié
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?